Genomic Translation for ALS Care
Genomic Translation for ALS Care
Sponsor: ALS Association
Enrolling: Male and Female Patients
IRB Number: AAAQ7026
U.S. Govt. ID: NCT02795897
Contact: Marie Likanje: 212-305-2202 /
Additional Study Information: The purpose of this study is to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress with a particular pattern. For up to three years, subjects will be followed every 3 months at the Columbia ALS Center or one of the study centers across the United States. They will undergo neurological examinations, complete questionnaires and have blood drawn.
This study is closed
Matthew Harms, MD
Do You Qualify?
Have you been diagnosed with amyotrophic lateral sclerosis, primary lateral sclerosis or related motor neuron disease? Yes No
Are you able to travel to Columbia or one of the other sites listed on Yes No
Are you willing to have your genome sequenced and shared with other researchers? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Marie Likanje